Skip to main content
SpringerLink
Log in

Brentuximab vedotin and hepatic disorders: WHO signal issued

  • Comment
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The recommended dose of brentuximab vedotin is 1.8 mg/kg given as IV infusion over 30 minutes every 3 weeks.

References

  1. Savage R. Brentuximab and Hepatic disorders. WHO Pharmaceuticals Newsletter : 17-20, No. 2, May 2015. Available from: URL: http://www.who.int/entity/medicines/publications/Pharm_Newsletter2_2015.pdf?ua=1

  2. Response from Takeda and Seattle Genetics (re: Brentuximab and Hepatic disorders). WHO Pharmaceuticals Newsletter : 20-22, No. 2, May 2015. Available from: URL: http://www.who.int/entity/medicines/publications/Pharm_Newsletter2_2015.pdf?ua=1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brentuximab vedotin and hepatic disorders: WHO signal issued. Reactions Weekly 1552, 1 (2015). https://doi.org/10.1007/s40278-015-0797-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-0797-1

Search

Navigation